- Home
- PPCB vs ADIL Comparison
PPCB vs ADIL Comparison
Compare PPCB & ADIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PPCB | ADIL |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7M | 6.4M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | PPCB | ADIL |
|---|---|---|
| Price | $0.22 | $0.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | ★ 565.5K | 314.3K |
| Earning Date | 02-15-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.24 | $0.21 |
| 52 Week High | $145.46 | $1.30 |
Technical Indicators
Market Signals| Indicator | PPCB | ADIL |
|---|---|---|
| Relative Strength Index (RSI) | 27.01 | 36.35 |
| Support Level | $0.24 | $0.21 |
| Resistance Level | $0.40 | $0.24 |
| Average True Range (ATR) | 0.06 | 0.01 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 7.08 | 14.07 |
Price Performance
Historical ComparisonAbout PPCB Propanc Biopharma Inc.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.